阿司匹林对表皮生长因子受体酪氨酸酶抑制剂 诱导小鼠皮疹的改善作用及其.

Objective To investigate the effect of aspirin in relieving skin rashes induced by epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in mice and the possible mechanism. Methods Fifty male Balb/c mice were randomly divided into the control group, model group, and high-dose, medium-dose, and low-dose aspirin groups, with 10 mice in each group. The skin rash models were established by administering the EGFR-TKI erlotinib to the mice in all the groups except the control group. After successful modeling, the mice in the high-, medium-, and low-dose aspirin groups were given aspirin at doses of 1. 13, 0. 75, and 0. 38 mg per mouse, respectively, while the mice in the control group were given distilled water at 100 mg/kg, all by gavage, once a day, for a total of 30 days. All the mice were monitored for feeding, drinking, urination, defecation, and mental status as well as pruritus and other skin conditions. The skin moisture level was measured using a skin moisture analyzer, and skin inflammation was scored. After the mice were sacrificed, the back skin was taken for observing the pathological changes with HE staining, and serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were determined by ELISA. Results In the control group, the skin and general conditions were normal; the mice in the model and low-dose aspirin groups developed skin rashes, scabs, and desquamation on the back, and began to have reduced food intake, increased water intake, increased urination, and reduced defecation since the first week, accompanied by anxiety and back scratching; compared with the model group, the medium- and high-dose aspirin groups showed significant improvements in skin rashes, scabs, and desquamation, and gradually returned to normal dieting since the second week. Only the model group had mild pruritus, while the other groups did not have any pruritus. No abnormal changes were found in any epidermal layer of the skin tissues in the control group; the model group showed epidermal thickening and substantial inflammatory cell infiltration in the dermis; the high dose and medium-dose aspirin groups showed slight epidermal thickening and mild inflammatory cell infiltration in the superficial dermis, while the low-dose aspirin group had a larger number of inflammatory cells in the superficial dermis; the levels of inflammation in the three aspirin groups were all lower than that in the model group. There was no significant difference in the skin moisture level between the groups (P<0. 05). The rash site, desquamation, exudation, skin thickening score, and serum levels of TNF-α and IL-1β were as follows： the control group < the high-dose aspirin group < the medium dose aspirin group < the low-dose aspirin group and model group (all P<0. 05). Conclusion Aspirin can alleviate EGFR-TKI-induced skin rashes in mice, possibly through reducing serum TNF-α and IL-1β levels and thereby inhibiting inflammatory response. [ABSTRACT FROM AUTHOR]